Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10296078 | 0.86 | SIGMAR1 (0.48) | SIGMAR1MC4RLMNAPOLBACHE | |
| SCHEMBL19116512 | 0.84 | ALDH1A1 (0.46) | SIGMAR1POLBDRD4TP53ALDH1A1 | |
| SCHEMBL1233809 | 0.83 | SIGMAR1 (0.46) | SIGMAR1MC4RLMNAPOLBACHE | |
| SCHEMBL5154581 | 0.83 | SIGMAR1 (0.50) | SIGMAR1MC4RLMNAPOLBACHE | |
| SCHEMBL19116976 | 0.83 | SIGMAR1 (0.50) | SIGMAR1MC4RLMNAPOLBACHE | |
| SCHEMBL21254439 | 0.82 | DRD2 (0.43) | SIGMAR1MC4RLMNAPOLBACHE | |
| SCHEMBL325929 | 0.82 | SIGMAR1 (0.48) | SIGMAR1MC4RLMNAPOLBDRD4 | |
| SCHEMBL6621542 | 0.78 | SIGMAR1 (0.52) | SIGMAR1MC4RLMNAPOLBACHE | |
| SCHEMBL19077905 | 0.74 | SIGMAR1 (0.47) | SIGMAR1MC4RLMNAPOLBACHE | |
| SCHEMBL27920146 | 0.74 | SIGMAR1 (0.51) | SIGMAR1MC4RLMNAPOLBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017120194-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | SIGMAR1 3726/4885MC4R 3462/4885LMNA 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.